Sedghizadeh receives $1.5 million for bone infection treatment
05 Sep 17
With help from the National Institutes of Health grant, the associate professor and his team aim to get FDA approval and bring the drug to market.
The novel treatment, featured earlier this year in the Journal of Medicinal Chemistry, pairs compounds from an antibiotic with those from a bisphosphonate (osteoporosis-treating medications) to target and deliver bacteria-killing medicine directly to the site of a bone infection.
Course after course of antibiotics
Currently, the main obstacle to treating bone-based bacterial infections (osteomyelitis) is that antibiotics do not enter bone — at least not at a high enough concentration to kill bacteria effectively. Instead, most antibiotics are released into the bloodstream, metabolized by the liver and then excreted.
To deliver a high enough concentration of antibiotics to be effective, patients must receive course after course of antibiotics, which can be quite expensive. It can also have potential side effects, including bacterial resistance and even, with enough exposure to antibiotics, patient toxicity.
In extreme cases, doctors may have to amputate bone tissue to extract the bacteria altogether before it consumes an entire bone, or, worse yet, the patient’s life.
An amazing homing drug
Sedghizadeh discovered a way to physiologically deliver the antibiotic and release it directly to the point of infection.
He worked with chemists to pair an antibiotic (ciprofloxacin) with a chemically inactive bisphosphonate (osteoporosis-treating medications) to create a compound that delivers the antibiotic right to the places it’s most needed.
“Bisphosphonates actually target sites of infection and inflammation in bone.” Sedghizadeh said. “They’re really amazing homing drugs.”
Initial results have been encouraging for Sedghizadeh.
“Just a single dose in vivo using this ‘targeting and release strategy’ killed 99 percent of bone-infecting bacteria and was an order of magnitude more deadly to the bacteria than ciprofloxacin alone, given in multiple doses,” he said.
With this NIH grant, Sedghizadeh plans to begin conducting larger animal in vivo studies and preparing data for eventual drug approval by the Food and Drug Administration.
“This grant means everything,” he said. “It allows further progress toward a commercial therapeutic that will impact human lives and reduce the morbidity and mortality associated with infectious bone disease.”
Sedghizadeh joined the Ostrow faculty in 2004. He is the director of the USC Center for Biofilms. His research subjects include biofilms, pathology, microbiology and infectious diseases.
Asha Green, Daniel Ip and Somkene Okwuego have their dental educations paid for, thanks to a National Health Service Corps scholarship that requires them to spend two years practicing in a health professional shortage area. IT’S A STATISTIC THAT’S NEVER FAR from the mind of Asha Green DDS ’26: just 3.7 percent of dentists in […]
Zhaoyang Liu Assistant Professor LAST YEAR, Ostrow welcomed researcher Zhaoyang Liu to the Trojan Dental Family. The tenure-track assistant professor earned her bachelor’s degree in biological sciences in China before pursuing a master’s degree in cellular, molecular and structural biology from Miami University-Ohio and a doctorate in biology from the University of Rochester-New York. […]
Alon Frydman PERIO ’06 Director, Continuing Education LAST YEAR, Ostrow’s CE department launched its official podcast, Louped In, which looks at various topics in dentistry from the foremost experts in the field. We caught up with its host, Associate Professor of Clinical Dentistry Alon Frydman. WHAT GOES INTO PREPARING FOR RECORDING AN EPISODE […]
The new tech allows endodontists to see in three dimensions, allowing more accurate diagnoses, treatment and evaluation. ENDODONTISTS SPECIALIZE IN SAVING NATURAL DENTITION, mostly focusing on the tooth’s interior. They live and die by imaging, both to diagnose what’s going on inside a tooth as well as to see how a treatment is working. Historically, […]
USC researcher Dechen Lin has created miniature organs — with the hope of fighting a rare type of cancer. CANCERS THAT IMPACT THE JUNCTION of the esophagus and the stomach are rare — but debilitating. They get less attention than breast, prostate or lung cancers — and 85 percent of patients diagnosed with gastroesophageal junction […]